Vicuron Pharmaceuticals Appoints Alan W. Dunton, M.D., to Board of Directors
20 September 2004 - 5:00PM
PR Newswire (US)
Vicuron Pharmaceuticals Appoints Alan W. Dunton, M.D., to Board of
Directors KING OF PRUSSIA, Pa., Sept. 20 /PRNewswire-FirstCall/ --
Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today
announced that the company appointed Alan W. Dunton, M.D. to its
board of directors. "We are excited to have someone of Alan's
stature and consistent accomplishment on our board," said George F.
Horner, III, President and CEO of Vicuron. "He has decades of
experience developing some of the top-selling drugs in the
industry, including a major community antibiotic, and leads a
private clinical-stage biopharmaceutical company of his own. His
world-class clinical development track record, in-depth commercial
knowledge and pipeline-building capability will be of substantial
value as we develop and seek to commercialize our own promising
pipeline of antimicrobial agents." Dr. Dunton is a recognized
leader in drug development and clinical research. His 20 years of
experience have been marked by the development and approval of the
prescription drugs Levaquin(R), Topamax(R), Reminyl(R),
Regranex(R), Risperdal(R) as well as the successful OTC product,
Aleve(R). He was named President and Chief Executive Officer of
MetaPhore Pharmaceuticals, Inc., a private biopharmaceutical
company, in February 2003. Prior to MetaPhore, Dr. Dunton held
numerous leadership positions, including President and Chief
Operating Officer of Emisphere Technologies, Inc.; President and
Managing Director of the Janssen Research Foundation, a Johnson
& Johnson company; and executive positions at Roche, CIBA-GEIGY
(now Novartis), and Syntex. Dr. Dunton received his Medical Degree
from New York University School of Medicine in 1980 and completed
his post-graduate training in Internal Medicine at the New York
University Medical Center/Bellevue Hospital VA Medical Center, and
a fellowship in Clinical Pharmacology at Cornell University/Medical
College/New York Hospital. About Vicuron Vicuron Pharmaceuticals is
a biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from
the FDA for its lead product anidulafungin for the treatment of
esophageal candidiasis. The company's other lead product,
dalbavancin, a novel intravenous antibiotic for the treatment of
serious Gram-positive infections, has completed Phase III clinical
trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel
and next- generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has
research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis. Forward-Looking Statements
This news release contains forward-looking statements that predict
or describe future events or trends. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are
beyond Vicuron's control. Vicuron faces many risks that could cause
its actual performance to differ materially from the results
predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be
delayed, that the timing of the filing of any new drug application
might be delayed, that subsequent clinical trials might indicate
that a product candidate is unsafe or ineffective, that any filed
new drug application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that a third party may not be willing to license
our product candidates on terms acceptable to us or at all, that
competitors might develop superior substitutes for their products
or market them more effectively, that a sales force may not be
developed as contemplated and that one or more of its product
candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which
Vicuron is subject. Because of those risks, Vicuron's actual
results, performance or achievements may differ materially from the
results, performance or achievements contemplated by its
forward-looking statement. The information set forth in this news
release represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to
the forward-looking matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein,
M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or Hala
Bashir of WeissComm Partners, +1-212-204-2080, or , or Aline
Schimmel of Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/
Copyright